In a phase 3 trial of 367 adults with mild-to-moderate atopic dermatitis, ivarmacitinib ointment 0.5% and 1% raised week-8 IGA response vs vehicle (21.3% and 26.2% vs 10.6%) and EASI 75 (42.6% and 45.1% vs 17.9%).
RCTn = 367
Wang et al. Ivarmacitinib ointment in treatment of adults with mild-to-moderate atopic dermatitis: phase III of a randomized double-blind placebo-controlled phase II/III clinical trial